Detecting gene-gene interactions in prostate disease in African American men

Infectious Agents and Cancer

Volumn 6, Issue SUPPL. 2, 2011, Pages

  Reams, R ^a   Kalari, Krishna ^b   Wang, Honghe ^c   Odedina, Folakemi T ^d,e   Soliman, Karam Fa ^a   Yates, Clayton ^c  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c TUSKEGEE UNIVERSITY   (United States)

^d UNIVERSITY OF FLORIDA HEALTH   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE;

ABCD GENE; AFRICAN AMERICAN; CAUCASIAN; CONFERENCE PAPER; CORRELATION ANALYSIS; GENE; GENE EXPRESSION; GENE INTERACTION; GENOTYPE; HEALTH DISPARITY; HUMAN; HUMAN CELL; MALE; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE DISEASE; RACE DIFFERENCE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 80053256325     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-6-S2-S1     Document Type: Conference Paper

References (63)

1. American Cancer Society Facts and Figures (2008). Atlanta: American Cancer Society
2. Keynote address: prostate cancer among African-American men - from the bench to the community. Prostate cancer and African-American men. Powell IJ, Oncology (Williston Park) 1997 11 5 599 605 discussion 606-15 passim. Review.PMID: 9159788
3. Prostate cancer in the African American: is this a different disease? Powell IJ, Semin Urol Oncol 1998 16 4 221 6 Review.PMID: 9858329 9858329 (Pubitemid 28553369)
4. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Giovannucci E, Platz EA, Stampfer MJ, Chan A, Krithivas K, Kawachi I, et al. Urology 1999 53 121 5 doi:10.1016/S0090-4295(98)00468-3 10.1016/S0090-4295(98)00468-3 9886600 (Pubitemid 29016626)
5. Triplet repeat mutations in human disease. Caskey CT, Pizzuti A, Fu YH, Fenwick RG Jr, Nelson DL, Science 1992 256 5058 784 9 doi:10.1126/science. 1589758 10.1126/science.1589758 1589758
6. Racial variations in prostate cancer incidence and in hormonal system markers among male health professionals. Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E, J Natl Cancer Inst 2000 92 24 2009 17 doi:10.1093/jnci/92.24. 2009 10.1093/jnci/92.24.2009 11121463 (Pubitemid 32045897)
7. African-American males and prostate cancer: assessing knowledge levels in the community. Smith GE, DeHaven MJ, Grundig JP, Wilson GR, J Natl Med Assoc 1997 89 6 387 91 9195798 (Pubitemid 127455010)
8. Differences between African-American and Caucasian men participating in a community-based prostate cancer screening program. Barber KR, Shaw R, Folts M, Taylor DK, Ryan A, Hughes M, et al. J Community Health 1998 23 6 441 51 doi:10.1023/A:1018758124614 10.1023/A:1018758124614 9824793 (Pubitemid 28510067)
9. A comparison of prostate knowledge of African-American and Caucasian men: Changes from prescreening baseline to post-intervention. Abbott RR, Taylor DK, Barber K, Cancer J Sci Am 1998 4 3 175 7 9612599
10. Knowledge, attitudes, and screening practices among older men regarding prostate cancer. Steele CB, Miller DS, Maylahn C, Uhler RJ, Baker CT, Am J Public Health 2000 90 10 1595 600 10.2105/AJPH.90.10.1595 11029994
11. Correlates of actual and perceived knowledge of prostate cancer among African Americans. Agho AO, Lewis MA, Cancer Nurs 2001 24 3 165 71 doi:10.1097/00002820-200106000-00001 10.1097/00002820-200106000-00001 11409059 (Pubitemid 32499261)
12. Prostate carcinoma knowledge, attitudes, and screening behavior among African-American men in Central Harlem, New York City. Ashford AR, Albert SM, Hoke G, Cushman LF, Miller DS, Bassett M, Cancer 2001 91 1 164 72 doi:10.1002/1097-0142(20010101)91:1<164::AID-CNCR21>3.0.CO;2-A 10.1002/1097-0142(20010101)91:1<164::AID-CNCR21>3.0.CO;2-A 11148573 (Pubitemid 32052627)
13. Prostate cancer knowledge among multiethnic black men. Magnus M, J Natl Med Assoc 2004 96 5 650 6 15160980 (Pubitemid 38560911)
14. Uncovering myths and transforming realities among low-SES African-American men: Implications for reducing prostate cancer disparities. Richardson JT, Webster JD, Fields NJ, J Natl Med Assoc 2004 96 10 1295 302 15540880 (Pubitemid 39318957)
15. Culture, black men, and prostate cancer: What is reality? Woods VD, Montgomery SB, Belliard JC, Ramirez-Johnson J, Wilson CM, Cancer Control 2004 11 6 388 96 15625526 (Pubitemid 39602212)
16. Prostate cancer screening perceptions, knowledge, and behaviors among African American men: Focus group findings. Forrester-Anderson IT, J Health Care Poor Underserved 2005 16 4, Suppl A 22 30 doi:10.1353/hpu.2005.0122 10.1353/hpu.2005.0122 16327094 (Pubitemid 41820321)
17. Prostate cancer knowledge and beliefs among black and white older men in rural and urban counties. Jones AR, Shipp M, Thompson CJ, Davis MK, J Cancer Educ 2005 20 96 102 doi:10.1207/s15430154jce2002-10 10.1207/s15430154jce2002-10 16083373 (Pubitemid 41061252)
18. Awareness and use of prostate-specific antigen test among African-American men. Ross LE, Uhler RJ, Williams KN, J Natl Med Assoc 2005 97 7 963 71 16080666 (Pubitemid 40967400)
19. Impact of race, age, income, and residence on prostate cancer knowledge, screening behavior, and health maintenance in siblings of patients with prostate cancer. Pruthi RS, Tornehl C, Gaston K, Lee K, Moore D, Carson CC, et al. Eur Urol 2006 50 1 64 9 doi:10.1016/j.eururo.2005.09.024 10.1016/j.eururo.2005.09. 024 16364537 (Pubitemid 43850104)
20. Contribution of socioeconomic status to Black/White differences in cancer incidence. McWhorter WB, Schatzkin AG, Horm JW, Brown CC, Cancer 1989 63 982 7 doi:10.1002/1097-0142(19890301)63:5<982::AID-CNCR2820630533>3.0.CO;2-I 10.1002/1097-0142(19890301)63:5<982::AID-CNCR2820630533>3.0.CO;2-I 2914303 (Pubitemid 19063213)
21. Socioeconomic factors and cancer incidence among Blacks and Whites. Baguet CR, Horm JW, Gibbs T, Greewald P, J Natl Cancer Inst 1991 83 551 7 doi:10.1093/jnci/83.8.551 10.1093/jnci/83.8.551 2005640
22. Race, prostate cancer survival, and membership in a large health maintenance organization. Robbins AS, Whittemore AS, Van Den Eeden SK, J Natl Cancer Inst 1989 90 13 986 90 doi:10.1093/jnci/90.13.986
23. Stage at presentation and survival of white and black patients with prostate carcinoma. Brawn PN, Johnson EH, Kuhl DL, Riggs MW, Speights VO, Johnson CFIII, et al. Cancer 1993 71 8 2569 73 doi:10.1002/1097-0142(19930415) 71:8<2569::AID-CNCR2820710822>3.0.CO;2-R 10.1002/1097-0142(19930415)71: 8<2569::AID-CNCR2820710822>3.0.CO;2-R 8453581 (Pubitemid 23100493)
24. Black-white differences in the stage at presentation of prostate cancer in the District of Columbia. Ndubuisi SC, Kofie VY, Andoh JY, Schwartz EM, Urology 1995 46 1 71 7 doi:10.1016/S0090-4295(99)80162-9 10.1016/S0090-4295(99) 80162-9 7544517
25. Race as an outcome predictor following radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Freedland SJ, Amling CL, Dorey F, Kane CJ, Presti JC, Terris MK, et al. Urology 2002 60 670 4 doi:10.1016/S0090-4295(02)01847-2 10.1016/S0090-4295(02)01847-2 12385931 (Pubitemid 35246456)
26. Black versus white racial differences in clinical stage at diagnosis and treatment of prostatic cancer in Connecticut. Polednak AP, Flannery JT, Cancer 1992 70 2152 8 doi:10.1002/1097-0142(19921015)70:8<2152::AID- CNCR2820700824>3.0.CO;2-# 10.1002/1097-0142(19921015)70:8<2152::AID- CNCR2820700824>3.0.CO;2-# 1394045
27. Prostate-specific antigen values at the time of prostate cancer diagnosis in African American men. Moul JW, Sesterhenn IA, Connelly RR, Douglas T, Srivastava S, Mostofi FK, et al. J Am Med Assoc 1995 274 1277 81 10.1001/jama.274.16.1277
28. Racial variation in cancer care: A case study of prostate cancer. Horner RD, Cancer Treat Res 1998 97 99 114 doi:10.1007/978-0-585-30498-4-8 10.1007/978-0-585-30498-4-8 9711412
29. The epidemiology of prostate cancer part II: The risk factors. Brawley OW, Knopf K, Thompson I, Semin Urol Oncol 1998 16 193 201 9858325 (Pubitemid 28553365)
30. Race and cause specific survival with prostate cancer: Influence of clinical stage, Gleason score, age and treatment. Fowler JE Jr, Bigler S, Bowman G, Kilambi N, J Urol 2000 163 1 137 42 doi:10.1016/S0022-5347(05)67989-X 10.1016/S0022-5347(05)67989-X 10604331
31. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, et al. J Natl Cancer Inst 1995 87 9 652 61 doi:10.1093/jnci/87.9.652 10.1093/jnci/87.9.652 7752270
32. Explaining racial differences in prostate cancer in the United States: Sociology or biology? Freedland SJ, Isaacs WB, Prostate 2005 62 243 52 doi:10.1002/pros.20052 10.1002/pros.20052 15389726 (Pubitemid 40129062)
33. Racial differences in prostate cancer growth: Apoptosis and cell proliferation in Caucasian and African-American patients. Guo Y, Sigman DB, Borkowski A, Kyprianou N, Prostate 2000 42 130 6 doi:10.1002/(SICI)1097- 0045(20000201)42:2<130::AID-PROS7>3.0.CO;2-3 10.1002/(SICI)1097- 0045(20000201)42:2<130::AID-PROS7>3.0.CO;2-3 10617870 (Pubitemid 30056645)
34. Serum testosterone levels in healthy young black and white men. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B, J Natl Cancer Inst 1986 76 45 8 3455741 (Pubitemid 16156102)
35. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US White and Black males. Ross R, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, et al. Lancet 1999 339 887 9 doi:10.1016/0140-6736(92)90927-U
36. Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study. Reams RR, Agrawal D, Davis M, Yoder S, Odedina F, Kumar N, Higginbotham J, Akinremi T, Suther S, Soliman K, Infectious Agents and Cancer 2009 4 Suppl 1 3 19208208
37. Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S, Cancer Res 2008 68 3 927 936 10.1158/0008-5472.CAN-07-2608 18245496 (Pubitemid 351206772)
38. Enhanced expression of SOS1 is detectable in prostate cancer epithelial cells from African-American men. Timofeeva OA, Zhang X, Ressom HW, Varghese RS, Kallakury BV, Wang K, Ji Y, Cheema A, Jung M, Brown ML, Rhim JS, Dritschilo A, Int J Oncol 2009 35 4 751 60 19724911
39. SCAN: SNP and copy number annotation. Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, Nicolae DL, Dolan ME, Cox NJ, Bioinformatics 2010 26 2 259 62 Epub 2009 Nov 17.PMID: 19933162 [PubMed-indexed for MEDLINE] 10.1093/bioinformatics/btp644 19933162
40. Trait-Associated SNPs Are More Likely to Be eQTLs: Annotation to Enhance Discovery from GWAS. Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ, PLoS Genet 2010 6 4 1000888 doi:10.1371/journal.pgen.1000888 PMID 20369019 10.1371/journal.pgen.1000888 20369019
41. SCAN: SNP and copy number annotation. Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner E, Nicolae DL, Dolan ME, Cox NJ, Bioinformatics Advance Access published on November 17, 2009, doi:10.1093/bioinformatics/btp644 PMID 19933162
42. Genetic Architecture of Transcript-Level Variation in Humans. Duan S, Huang RS, Zhang W, Bleibel WK, Roe CA, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, Dolan ME, Amer. J. Human Genetics 2008 82 1101 1113 PMID 18439551 10.1016/j.ajhg.2008.03.006
43. Evaluation of Genetic Variation Contributing to Differences in Gene Expression Between Populations. Zhang W, Duan S, Kistner EO, Bleibel WK, Huang RS, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, Dolan ME, Amer. J. Human Genetics 2008 82 631 640 PMID 18313023 10.1016/j.ajhg.2007.12.015
44. SNPinProbe-1.0: A database for filtering out probes in the Affymetrix GeneChip(R) Human Exon 1.0 ST array potentially affected by SNPs. Duan S, Zhang W, Bleibel WK, Cox NJ, Dolan ME, Bioinformation 2008 2 10 469 70 PMID 18841244 18841244
45. Establishment and characterization of a pair of non-malignant and malignant tumor derived cell lines from an African American prostate cancer patient. Theodore S, Sharp S, Zhou J, et al. International journal of oncology 37 1477 82
46. Isolation of a human prostate carcinoma cell line (DU 145). Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF, International journal of cancer 1978 21 274 81 10.1002/ijc.2910210305 (Pubitemid 8283045)
47. Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice. Dondi D, et al. Int J Cancer 1998 76 4 506 11 10.1002/(SICI)1097-0215(19980518)76:4<506::AID-IJC11>3.0.CO;2-5 9590126 (Pubitemid 28227993)
48. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Jungwirth A, Pinski J, Galvan G, et al. Eur J Cancer 1997 33 1141 8 10.1016/S0959-8049(97)00072-5 9376196 (Pubitemid 27310789)
49. EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Turner T, Chen P, Goodly LJ, Wells A, Clinical & experimental metastasis 1996 14 409 18 10.1007/BF00123400 21837835 (Pubitemid 26363215)
50. Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Wells A, Welsh JB, Lazar CS, Wiley HS, Gill GN, Rosenfeld MG, Science 1990 247 962 964 10.1126/science.2305263 2305263
51. In Vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals. Xie H, Turner T, Wang MH, Singh RK, Siegal GP, Wells A, Clin Exp Metastasis 1995 13 6 407 19 10.1007/BF00118180 7586799
52. The LNCaP cell line - a new model for studies on human prostatic carcinoma. Horoszewicz JS, et al. Prog Clin Biol Res 1980 37 115 32 7384082
53. Significance analysis of micro arrays applied to the Ionizing radiation response. Tusher VG, Tibshirani R, Chu G, Proc Nation Acad Sci USA 2001 98 9 5116 21 10.1073/pnas.091062498 (Pubitemid 32397092)
54. Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, Yu D, Reams RR, Freedman ML, Rivers B, Green BL, Kumar N, Infect Agent Cancer 2009 10 4 Suppl 1 2
55. Expression profiling of ABC transporters in a drug-resistant breast cancer cell line using AmpArray. Liu Y, Peng H, Zhang JT, Mol Pharmacol 2005 68 430 8 15901850 (Pubitemid 41058306)
56. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ, Cancer research 2005 65 6640 50 10.1158/0008-5472.CAN-04-2548 16061644 (Pubitemid 41060700)
57. MiRNA 26a expression in a novel panel of African American prostate cancer cell lines. Theodore SC, Rhim JS, Turner T, Yates C, Ethn Dis 20 1 96-100
58. Rapid signalling by androgen receptor in prostate cancer cells. Peterziel H, Mink S, Schonert A, Becker M, Klocker H, Cato AC, Oncogene 1999 18 6322 9 10.1038/sj.onc.1203032 10597231
59. Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Odero-Marah VA, Wang R, Chu G, et al. Cell Res 2008 18 858 70 10.1038/cr.2008.84 18645583
60. Racial disparity of epidermal growth factor receptor expression in prostate cancer. Shuch B, Mikhail M, Satagopan J, et al. J Clin Oncol 2004 22 4725 9 10.1200/JCO.2004.06.134 15570072 (Pubitemid 41185082)
61. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Gan Y, Shi C, Inge L, Hibner M, Balducci J, Huang Y, Oncogene 29 4947 58
62. Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline. Yates C, Wells A, Turner T, British journal of cancer 2005 92 366 15655536
63. Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Yates CC, Shepard CR, Stolz DB, Wells A, British journal of cancer 2007 96 1246 52 10.1038/sj.bjc.6603700 17406365 (Pubitemid 46625074)